contact us
rémun
Since 1992, we have been sharing our cutting-edge knowledge in all our areas of expertise. Normandin Beaudry sets itself apart as a firm that is committed to straight talk: we’re always there in black and white.
Explore our areas of expertise
We create human capital and financial performance with our clients through the excellence of our experts ignited by a total rewards mindset.
1992
Normandin Beaudry is founded
Owned exclusively by its professionals
Count on the presence and stability of key employees
More than 250 employees
ignited by a total rewards mindset
A visionary leader
in total rewards and actuarial consulting
An enviable roster of Canadian clients
Major corporations, SMBs, para-governmental organizations, municipalities and non-profit organizations
8 areas of expertise
- Health
- Performance
- Group Benefits
- Investment Consulting
- Compensation
- Communication
- Pension and Savings
- Pension Plans Administration
Join the NB team!
_
Bill 132: amendments to the Pension Benefits Act of Ontario
On October 28, 2019, Bill 132 (An Act to reduce burdens on people and businesses by enacting, amending and repealing various Acts and revoking various Regulations) was introduced in the Legislative Assembly of Ontario.
Read more
_
Good News for Retirement Security — A new option will soon be available in Quebec
On November 7, the Quebec Minister of Finance presented his economic update on Quebec’s finances. The Minister, who is also responsible for Retraite Québec, had good news in this regard.
The Minister confirmed the Government of Quebec’s desire to offer a new pension plan option for Quebec employers and workers. In this respect, the government will propose a regulatory framework to introduce target benefit plans (TB plans).
Read more
_
Biosimilars: Further steps taken by British Columbia and Alberta
In September 2019, the Government of British Columbia added two major medical conditions to its rules concerning the switch to biosimilars. People who use Remicade to treat ulcerative colitis and Crohn’s disease will have to modify their prescription and switch to the biosimilar version of their medication by March 5, 2020. The use of original biologics will be allowed for exceptional medical reasons only.
Read more